Gene therapy of severe combined immunodeficiencies

被引：47

作者：

Fischer, A ^{[1
]}

Hacein-Bey, S ^{[1
]}

Cavazzana-Calvo, M ^{[1
]}

机构：

[1] Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France

来源：

NATURE REVIEWS IMMUNOLOGY | 2002年 / 2卷 / 08期

关键词：

D O I：

10.1038/nri859

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The concept that the outcome of a devastating disease can be modified by inserting a transgene into abnormal cells is appealing. However, the gene-transfer technologies that are available at present have limited the success of gene therapy so far. Nevertheless, severe combined immunodeficiencies are a useful model, because gene transfer can confer a selective advantage to transduced cells. In this way, a proof of concept for gene therapy has been provided.

引用

页码：615 / 621

页数：7

共 63 条

[1] Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A
Slavin, S
Aker, M
Ficara, F
Deola, S
Mortellaro, A
Morecki, S
Andolfi, G
Tabucchi, A
Carlucci, F
Marinello, E
Cattaneo, F
Vai, S
Servida, P
Miniero, R
Roncarolo, MG
Bordignon, C
[J]. SCIENCE, 2002, 296 (5577) : 2410 - 2413
[2] Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement
Aiuti, A
Vai, S
Mortellaro, A
Casorati, G
Ficara, F
Andolfi, G
Ferrari, G
Tabucchi, A
Carlucci, F
Ochs, HD
Notarangelo, LD
Roncarolo, MG
Bordignon, C
[J]. NATURE MEDICINE, 2002, 8 (05) : 423 - 425
[3] LEUKOCYTE ADHESION DEFICIENCY - AN INHERITED DEFECT IN THE MAC-1, LFA-1, AND P150,95 GLYCOPROTEINS
ANDERSON, DC
SPRINGER, TA
[J]. ANNUAL REVIEW OF MEDICINE, 1987, 38 : 175 - 194
[4] Bauer TR, 2000, CURR OPIN MOL THER, V2, P383
[5] Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral blood CD34+ cells derived from a patient with leukocyte adhesion deficiency type 1
Bauer, TR
Schwartz, BR
Liles, WC
Ochs, HD
Hickstein, DD
[J]. BLOOD, 1998, 91 (05) : 1520 - 1526
[6] Blackburn MR, 1997, DEVELOPMENT, V124, P3089
[7] Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency
Blackburn, MR
Datta, SK
Kellems, RE
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) : 5093 - 5100
[8] T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS
BLAESE, RM
CULVER, KW
MILLER, AD
CARTER, CS
FLEISHER, T
CLERICI, M
SHEARER, G
CHANG, L
CHIANG, YW
TOLSTOSHEV, P
GREENBLATT, JJ
ROSENBERG, SA
KLEIN, H
BERGER, M
MULLEN, CA
RAMSEY, WJ
MUUL, L
MORGAN, RA
ANDERSON, WF
[J]. SCIENCE, 1995, 270 (5235) : 475 - 480
[9] HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
Bonini, C
Ferrari, G
Verzeletti, S
Servida, P
Zappone, E
Ruggieri, L
Ponzoni, M
Rossini, S
Mavilio, F
Traversari, C
Bordignon, C
[J]. SCIENCE, 1997, 276 (5319) : 1719 - 1724
[10] GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS
BORDIGNON, C
NOTARANGELO, LD
NOBILI, N
FERRARI, G
CASORATI, G
PANINA, P
MAZZOLARI, E
MAGGIONI, D
ROSSI, C
SERVIDA, P
UGAZIO, AG
MAVILIO, F
[J]. SCIENCE, 1995, 270 (5235) : 470 - 475

← 1 2 3 4 5 6 7 →